Strides to conduct clinical trials for potential Covid-19 drug in India
Glenmark was the first Indian firm to get approval from regulator to conduct trials on Favipiravir tablets, which are otherwise used to treat influenza21-05-2020
21-05-2020
Glenmark commences late-stage trial on Covid-prospective drug Favipiravir
Glenmark Pharmaceuticals has initiated late-stage Phase-III clinical trials on the antiviral Favipiravir to test its efficacy in patients showing mild12-05-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India12-05-2020
Glenmark launches 3-in-1 inhaler for COPD patients in India
Glenmark Pharmaceuticals on Monday said it has launched a triple therapy inhaler in the country for patients with chronic obstructive pulmonary disease (COPD).11-05-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function11-05-2020
Glenmark Pharma jumps 9% on DCGI nod
The company said it is the first firm in India to receive such an approval from the DCGI.30-04-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients30-04-2020
Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tablets
Glenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin and Saxaglip29-04-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg29-04-2020
GLENMARK PHARMACEUTICALS LTD. - 532296 - Shareholding for the Period Ended March 31, 2020
Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here22-04-2020